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Abstract
Background: Allopurinol has vascular antioxidant effects and participates in purinergic signalling within muscle. We tested
whether allopurinol could improve skeletal muscle energetics and physical function in older people with impaired physical
performance.
Methods: We conducted a randomised, double blind, parallel group, placebo-controlled trial, comparing 20 weeks of
allopurinol 600 mg once daily versus placebo. We recruited community-dwelling participants aged 65 and over with baseline
6-min walk distance of<400 m and no contraindications to magnetic resonance imaging scanning. Outcomes were measured
at baseline and 20 weeks. The primary outcome was post-exercise phosphocreatine (PCr) recovery rate measured using 31P
magnetic resonance spectroscopy of the calf. Secondary outcomes included 6-min walk distance, short physical performance
battery (SPPB), lean body mass measured by bioimpedance, endothelial function and quality of life.
Results: In total, 124 participants were randomised, mean age 80 (SD 6) years. A total of 59 (48%) were female, baseline
6-min walk distance was 293 m (SD 80 m) and baseline SPPB was 8.5 (SD 2.0). Allopurinol did not significantly improve
PCr recovery rate (treatment effect 0.10 units [95% CI, −0.07 to 0.27], P = 0.25). No significant changes were seen in
endothelial function, quality of life, lean body mass or SPPB. Allopurinol improved 6-min walk distance (treatment effect
25 m [95% 4–46, P = 0.02]). This was more pronounced in those with high baseline oxidative stress and urate.
Conclusion: Allopurinol improved 6-min walk distance but not PCr recovery rate in older people with impaired physical
function. Antioxidant strategies to improve muscle function for older people may need to be targeted at subgroups with high
baseline oxidative stress.
Keywords:allopurinol, physical performance, oxidative stress, skeletal muscle, older people
Key Points
• Oxidative stress has been implicated in muscle dysfunction and allopurinol has been shown to reduce oxidative stress in
other organ systems with clinical benefit.
• Allopurinol did not improve PCr recovery rate (a measure of skeletal muscle mitochondrial function).
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• Six-min walk distance improved by a small but clinically significant amount but other measures of physical performance
were unchanged.
• Future studies should target older people with high baseline levels of oxidative stress.
Introduction
Impaired physical performance is common with increasing
age, and reduction in skeletal muscle function (part of
the syndrome of sarcopenia) is a key contributor to this
decline. Improving impaired physical function and prevent-
ing decline in physical function are key goals in maintaining
health and wellbeing for a wide range of older people.
Although regular exercise has been shown to increase muscle
strength and to slow functional decline [1], the majority of
older people are sedentary and often unable or unwilling
to contemplate adequate exercise participation [2]. Alterna-
tive strategies to improve physical function are required to
minimise dependency and maximise independence.
Allopurinol is a purine analogue that has been used to
prevent gout for decades. It is a powerful inhibitor of xan-
thine oxidoreductase in both its forms—as xanthine dehy-
drogenase and as xanthine oxidase (XO). Inhibition of this
key enzyme in the degradation of purines to urate low-
ers both urate as well as reactive oxygen species (ROS),
which is a by-product of XO catalytic action. There are
three reasons why allopurinol might be beneficial in ageing
muscle. Firstly, skeletal muscle is particularly susceptible
to oxidative stress mainly due to the rapid flux of oxygen
and the balance of energy supply/demand. Previous studies
have shown that oxidative stress is implicated in reduced
quadriceps endurance [3]. XO is a major generator of free
radicals; up-regulation of XO and increased oxidative stress
are found in ageing muscles and this mechanism has been
implicated in sarcopenia [4]. Therefore, reducing muscle
oxidative damage might be expected to result in reduced
muscle dysfunction, increased muscle contractile efficiency
and reduced functional impairment.
Secondly, animal studies have previously demonstrated
that allopurinol decreased free adenosine diphosphate (ADP)
levels needed to drive adenosine triphosphate (ATP) synthe-
sis, and normalised muscle phosphocreatine (PCr)-to-ATP
ratio (PCr/ATP) [5]. These findings would be compatible
with a beneficial effect of allopurinol on mitochondrial
function, perhaps due to the reduction in oxidative stress
described above. Suppression of XO with allopurinol has
indeed been shown to increase maximal isometric force in
plantar flexion in animal models [6], and allopurinol use
was associated with greater functional gains in older patients
undergoing rehabilitation in an observational study [7].
Thirdly, we have previously shown that allopurinol
improves vascular endothelial function in various inter-
vention studies enrolling older people with established
cardiometabolic disease [8–11]. An improvement in muscle
perfusion could also potentially improve muscle function,
particularly given the high prevalence of vascular dysfunction
found in older people. Therefore, we conducted this
present study in older people with functional impairment
to determine whether treatment with allopurinol could
improve physical function, and to study the mechanism
by which it might achieve this. We hypothesised that
allopurinol would improve the initial rate of skeletal muscle
PCr recovery after exercise (a measure of mitochondrial
function) compared to placebo.
Methods
Study design
We performed a randomised, double-blinded, parallel-
group, placebo-controlled trial between February 2016
and August 2017. Ethics approval was obtained from
East of Scotland Research Ethics committee (approval
number 14/ES/1092), and regulatory approval was obtained
from the Medicines and Healthcare products Regulatory
Agency (Clinical Trials Authorisation 2014-004122-18).
It was carried out in accordance with the declaration of
Helsinki. Written informed consent was obtained from all
participants at the screening visit. The trial was funded by
Dunhill Medical Trust (Grant Ref: R315/1113) and trial
management support was provided by Tayside Clinical
Trials Unit. The trial was registered at www.isrctn.com
(ISRCTN03331094).
Population and recruitment
Participants were eligible if they were aged 65 or over, with
a 6-min walk distance of <400 m based on the study
conducted by Newman et al [12]. Exclusion criteria were
conditions likely to provide alternative causes for poor
exercise tolerance and muscle dysfunction: a documented
history of peripheral arterial disease, severe heart failure
(left ventricular ejection fraction< 35%), malignancy under
active treatment, severe chronic obstructive pulmonary
disease (COPD) or long-term use of steroids (prednisolone
equivalent of 10 mg/day or more). Other exclusion criteria
were for safety reasons: intolerance to allopurinol, any use of
allopurinol within the last 30 days, current use of azathio-
prine, 6-mercaptopurine or theophyllines or an estimated
glomerular filtration rate (eGFR) of 30 ml/min/1.73 m2
or less. Participants unable to perform the short physical
performance battery (SPPB) or 6-min walk tests (6MWTs)
without human assistance were excluded, as were those with
contraindications to magnetic resonance imaging scanning,
cognitive impairment precluding giving written informed
consent, those who had participated in another clinical
drug trial within the preceding 30 days and those with
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active acute gout. Participants were recruited via hospital
outpatient clinics, newspaper advertisements to the local
community and from primary care practice database searches
conducted by the NHS Research Scotland Primary Care
Network (NRSPCN).
Intervention and comparator
Matching capsules containing either 300 mg of allopurinol
or placebo that appeared identical (Tayside Pharmaceuticals,
Dundee, UK) were dispensed in identical bottles that had
no indication of treatment allocation. Participants took one
capsule each day for the first 4 weeks. If renal function
remained stable and no side effects were noted, partici-
pants then took two capsules once a day for the remaining
16 weeks. Participants were permitted to continue their usual
medication throughout the trial.
Randomisation and allocation concealment
Randomisation was performed in a 1:1 ratio by a web-
based GCP compliant randomisation system (TRuST,
Health Informatics Centre, University of Dundee) to ensure
allocation concealment. A minimisation algorithm with a
small random element was used to ensure balance across
key baseline measures. Minimisation factors used were male
versus female sex and baseline 6-min walk distance of less
than or more than 200 m.
Outcomes
All outcomes were measured at baseline and at 20 weeks.
Details of the methods used for outcomes measures are given
in Supplementary Material A1 [13–20]. The pre-specified
primary outcome was the initial rate of PCr recovery
(ViPCR). Secondary outcomes were the 6-min walk distance
[16], SPPB [17], lean body mass derived from bioimpedance
using the Sergi equation [18], endothelial function [19] and
health-related quality of life measured using the EQ5D tool
[20]. All outcomes were assessed by a research fellow blinded
to intervention group, and investigators remained blinded to
treatment allocation until after completion of the statistical
analysis.
Sample size calculation
The sample size was calculated based on detecting a 20%
difference between groups in the primary outcome of initial
PCr resynthesis rate (ViPCR). Data published by Layec
et al . [3] showed ViPCr values in healthy older people
(74± 17%/min) versus COPD patients (52± 13%/min)
i.e. a 42% difference between healthy older people and
patients with COPD. A conservative approach would be
to assume that functionally impaired older people have less
severe impairment than people with COPD. We therefore
assumed 20% difference between healthy older people and
functionally impaired older people on allopurinol. To detect
this difference with 90% power at a significance level of
α = 0.05 requires 44 participants per group. Allowing for a
20% dropout rate, we required 110 participants. To ensure
a further buffer against technical failure or uninterpretable
MR spectroscopy results, the final sample size was set at
124 participants, which also gave sufficient power for key
secondary endpoints to detect a 2% absolute difference in
Flow-Mediated Dilatation (FMD) of the brachial artery [21]
and the minimum clinically important difference of 20m for
the 6-min walk [22].
Analysis
All analyses were performed using SPSS v24 (IBM, New
York, USA) according to a pre-specified statistical anal-
ysis plan. A P value< 0.05 was taken as significant for
all analyses. Descriptive statistics were generated for both
groups at baseline; comparisons between baseline groups
were performed using Student’s t-test for continuous vari-
ables if normally distributed, and Mann–Whitney U test
for non-normally distributed variables. Categorical variables
were compared using Pearson’s chi-square test. The primary
and secondary analyses were performed by modified inten-
tion to treat, including all participants with follow-up data.
For normally distributed variables, general linear models
were used to compare results between groups at 20 weeks,
adjusted for baseline values. Several of the magnetic res-
onance spectroscopy (MRS) variables were not normally
distributed, but instead conformed to a gamma distribution.
These variables were compared using generalised linear mod-
els, adjusting for baseline values of the variable under test,
using a gamma distribution and log link function. Estimated
marginal means were generated to convey treatment effect
size. Several sensitivity analyses were performed for the pri-
mary outcome. Multiple imputations (10 imputations) were
performed using baseline ViPCr, age, sex, baseline 6-min
walk distance and SPPB to impute missing ViPCr values.
A per-protocol analysis was also performed, including only
those participants still taking the full dose of study medica-
tion at the final visit, and with adherence> 80%. Statistical
analyses were performed blinded to treatment allocation,
and unblinding of the analysis took place only after analysis
completion.
Results
A total of 265 individuals expressed interest in participating,
of whom 142 attended a screening visit and 124 were
randomised. Baseline data on the randomised population
are given in Table 1, and Figure 1 shows participant flow
through the trial. A total of 116 individuals (58/62 in the
allopurinol arm and 58/62 in the placebo arm) attended
the final study visit. Adherence to the study medications
was excellent; mean adherence in the allopurinol group was
93% (SD 12%), compared to 95% (SD 12%) in the placebo
group (P = 0.32).
Primary outcome
There was no significant difference between the allopurinol
and placebo groups in the ViPCR corrected for baseline
ViPCr (Table 2).
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Table 1. Baseline details
Allopurinol (n = 62) Placebo (n = 62) P
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mean age (years) (SD) 79.9 (5.3) 80.6 (6.6) 0.55
Female sex (%) 29 (47) 30 (48) 0.86
Ischaemic heart disease (%) 8 (13) 12 (19) 0.33
Hypertension (%) 42 (68) 33 (53) 0.10
Dyslipidaemia (%) 34 (55) 33 (53) 0.86
Stroke or TIA (%) 7 (11) 6 (10) 0.77
Diabetes mellitus (%) 10 (16) 10 (16) 1.00
Median weekly alcohol intake (units) (IQR) 2 (1–8) 2 (0–5) 0.38
Current smoker (%) 3 (5) 5 (8) 0.47
Systolic BP (mmHg) (SD) 141 (15) 146 (20) 0.14
Diastolic BP (mmHg) (SD) 78 (10) 76 (10) 0.49
Body Mass Index (kg/m2) (SD) 28.5 (4.6) 28.1 (4.9) 0.59
Six-min walk distance (m) 295 (80) 290 (79) 0.75
Muscle mass (kg) (SD) Males 11.6 (2.3) 11.2 (2.4) 0.50
Females 9.9 (1.8) 10.1 (1.6) 0.72
SPPB (SD) 8.6 (2.0) 8.4 (2.0) 0.69
Median total number of medications (IQR) 5 (3–8) 5 (3–8) 0.90
Medications:
Angiotensin converting enzyme inhibitor 15 (24) 17 (27) 0.68
Beta blocker 9 (15) 12 (19) 0.47
Calcium channel blocker 22 (35) 17 (27) 0.33
Alpha blocker 7 (11) 5 (8) 0.76
Thiazide 14 (23) 15 (24) 0.83
Loop diuretic 5 (8) 5 (8) 1.00
Aldosterone antagonist 2 (3) 2 (3) 1.00
Angiotensin receptor blocker 6 (10) 5 (8) 0.75
Statin 29 (47) 23 (37) 0.28
Antiplatelet 14 (23) 16 (26) 0.68
Insulin 2 (3) 0 (0) 0.50
Antidiabetic 6 (10) 6 (10) 1.00
Independent t-test, Mann–Whitney test or Pearson’s chi-squared (Fisher’s exact where cell value is <5). SD, standard deviation; TIA, transient ischemic attack;
IQR, interquartile range.
Table 2. Primary outcome: effect of treatment on measures of PCr recovery rate
Allopurinol (median, IQR) Placebo (median, IQR) Treatment effecta (95% CI) p
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Normalised ViPCr Baseline 0.50 (0.33–0.83) 0.60 (0.35–0.78) 0.10 (−0.07 to 0.27) 0.25
20 weeks 0.60 (0.33–0.94) 0.59 (0.43–0.82)
Sensitivity analyses
Normalised ViPCr—multiply
imputed
0.08 (−0.09 to 0.26) 0.36
Normalised ViPCr—per protocol Baseline 0.50 (0.31–0.99) 0.54 (0.32–0.76) 0.10 (−0.07 to 0.27) 0.27
20 weeks 0.63 (0.36–0.96) 0.58 (0.43–0.82)
Un-normalised ViPCr Baseline 23,385 (5419–38,668) 20,681 (3821–33,521) 5715 (−3674 to 15,104) 0.23
20 weeks 28,227 (16818–51,171) 29,005 (17810–42,279)
aEstimated marginal mean from generalised linear model using gamma distribution with log link. Multiple imputations (10 imputations) using baseline ViPCr,
age, sex, baseline 6-min walk and SPPB to impute missing ViPCr.
Subgroup and sensitivity analyses
Pre-specified subgroup analyses for the primary outcome are
shown in Supplementary Material A2. The only significant
subgroup interaction was with baseline 6-min walk distance,
where those with the lowest walk distance (<200 m) showed
deterioration in ViPCr with treatment, in contrast to those
with a baseline walk distance of >300 m (P = 0.05 for
interaction). For the per-protocol sensitivity analysis, a total
of 98 participants were included (44 in the allopurinol arm
and 54 in the placebo arm). Results for this analysis are
shown in Table 2.
Secondary outcomes
Non-MRS secondary outcomes are shown in Table 3. Allop-
urinol caused a large reduction in serum urate compared
to the placebo group as expected. Six-min walk distance
improved in the allopurinol group compared to placebo;
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Figure 1. CONSORT diagram of participant flow through the trial
the treatment effect (25 m) was statistically significant and
exceeded the minimum clinically important difference of
20 m. Post hoc exploratory subgroup analyses of the 6-
min walk distance suggested that the difference in 6MWT
was significantly greater in participants who had higher
baseline muscle oxidative stress (8-hydroxydeoxyguanosine
(8-OHDG)> 233 ng/ml) and baseline urate (>0.41
mmol/L) (Supplementary Material A3). A weak correlation
(rho = 0.18, P = 0.06) was seen between change in ViPCr
and change in 6-min walk distance. Other measures of
oxidative stress, endothelial function, physical performance,
lean body mass and quality of life did not improve with
allopurinol relative to placebo. Alternative MRS measures of
muscle energetics are shown in Supplementary Material A4;
no significant treatment effect was seen on any marker.
Adverse events
Adverse events are shown aggregated into MedDRA system-
organ-class categories in Supplementary Material A5. More
adverse events were seen in the allopurinol arm, driven by a
higher frequency of skin, gastrointestinal and vascular events.
Discussion
The main finding from this present study is that allopurinol
did not improve muscle efficiency as measured by initial
rate of PCr recovery in older participants with functional
impairment. However, it improved the 6MWT distance and
this improvement was more pronounced in those with a
higher baseline oxidative stress and urate level. This would
suggest that the mechanism of improvement may not be
by ADP-sparing and improved PCr recycling but rather via
an alternative antioxidant mechanism. We have previously
demonstrated in a heart failure cohort that allopurinol at
this high dose functions as an effective antioxidant, capable
of abolishing Vitamin C-sensitive component of vascular
oxidative stress [8]. Urate is an abundant and potent aqueous
antioxidant in humans, although its importance as a major
antioxidant in vivo is unclear [23,24]. It is possible that
reducing urate in normouricemic patients with low back-
ground oxidative stress, who rely on urate for antioxidant
defence, will negate any direct reduction in ROS genera-
tion by XO inhibition, leading to an overall null effect on
oxidative stress, mitochondrial function and therefore PCr
recovery. This could also explain the non-significant increase
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Table 3. Secondary outcomes
Allopurinol (SD) Placebo (SD) Treatment effect (95% CI) P
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Six-min walk (m) Baseline 295 (80) 290 (79) 25 (4 to 46) 0.02
20 weeks 366 (95) 340 (85)
Lean body mass (kg/m2) Baseline 10.8 (2.3) 10.7 (2.1) 0.1 (−0.5 to 0.7) 0.70
20 weeks 10.6 (2.0) 10.4 (2.0)
SPPB Baseline 8.6 (2.0) 8.4 (2.0) 0.0 (−0.5 to 0.5) 0.91
20 weeks 9.3 (1.8) 9.1 (1.9)
EQ5D health state Baseline 0.78 (0.20) 0.77 (0.23) 0.02 (−0.03 to 0.07) 0.41
20 weeks 0.81 (0.14) 0.80 (0.20)
EQ5D thermometer Baseline 78 (15) 78 (14) 2 (−2 to 6) 0.32
20 weeks 79 (14) 78 (13)
Systolic BP (mmHg) Baseline 141 (15) 146 (20) 0 (−5 to 5) 0.94
20 weeks 143 (15) 145 (17)
Diastolic BP (mmHg) Baseline 78 (10) 76 (10) -1 (−4 to 2) 0.66
20 weeks 76 (10) 76 (11)
FMDa (%) Baseline 7.50 (3.86) 7.59 (3.95) −0.63 (−2.11 to 0.84) 0.39
20 weeks 6.92 (3.07) 7.45 (3.69)
FMD GTN (%) Baseline 14.88 (5.55) 17.09 (5.50) 2.23 (−0.57 to 5.03) 0.12
20 weeks 16.37 (5.30) 15.25 (6.64)
Urate (mmol/L) Baseline 0.38 (0.14) 0.42 (0.14) −0.12 (−0.16 to 0.08) <0.001
20 weeks 0.24 (0.16) 0.40 (0.15)
TBARS (uM) Baseline 2.94 (1.51) 3.09 (1.34) 0.09 (−0.38 to 0.56) 0.70
20 weeks 3.10 (1.68) 3.18 (1.51)
8OHDG Baseline 254 (107) 251 (104) 23 (−4 to 50) 0.10
20 weeks 292 (140) 258 (104)
BP, blood pressure; CI, confidence interval; EQ5D, EuroQoL 5-dimension score; FMD: flow-mediated dilatation of the brachial artery; GTN, glyceryl trinitrate;
TBARS, thiobarbiturate reactive substances. an = 43 for each group at baseline. Treatment effects adjusted for baseline value of variable under test.
in 8OHDG we saw with treatment. This phenomenon has
been previously demonstrated in another normouricemic
cohort with low oxidative stress [25].
We found an increase in the secondary outcome of
6MWT distance of 25 m in the allopurinol group compared
to placebo. Perera et al [22] suggest that a 20 m gain
in 6MWT is the minimum meaningful change in older
people. In this present study, this difference in 6MWT was
significantly greater in participants who had higher baseline
muscle oxidative stress and baseline urate, which suggests
that XO inhibition in these patients may be beneficial.
The lack of effect of allopurinol on PCr recovery rate
makes it unlikely that the improvement in 6-min walk
distance was driven by improved mitochondrial function
in normouricemic patients with low background oxidative
stress. One alternative explanation is that allopurinol may
have exerted improvements in exercise capacity via adenosine
receptors present in a variety of tissues including the heart
and skeletal muscle; it is noteworthy that caffeine (amolecule
in the xanthine family) is known to have beneficial effects on
exercise capacity. It is also possible that the improvement
in 6-min walk distance was a chance finding due to
testing multiple secondary outcomes; this finding requires
replication in future trials.
Future studies in older people should focus interven-
tions in those with high baseline oxidative stress and hype-
ruricemia. Unlike previous studies in cohorts with estab-
lished disease [8,26], we did not observe an improvement in
vascular endothelial function in this cohort which suggests
that any functional improvement seen in this study is not
directly attributable to improvements in muscle blood flow.
Markers of ATP depletion such as the rate constant k, Pi/PCr
ratio and amount of β-ATP depletion post-exercise were not
significantly different between groups indicating that ATP
sparing may not be the mechanism by which allopurinol
improved walk distance.
Limitations
Preclinical work suggests that allopurinol might improve
muscle function by reduction of XO-derived oxidative stress
[6,27,28]. There are several reasons why we may not have
detected this improvement in this present study. Only two
men and no women met the clinical definition for sarcope-
nia and therefore it is possible that individuals with more
impaired muscle physiology (i.e. those with sarcopenia) may
have demonstrated greater improvement in muscle efficiency
with allopurinol. The half-time recovery for PCr at base-
line in our study was relatively preserved, suggesting that
a ceiling effect may have limited the ability of allopurinol
to improve measures of mitochondrial function. A previous
study showed that patients with sarcopenia have impaired
endothelial function, a measure upon which allopurinol has
repeatedly demonstrated a beneficial effect [29]. We delib-
erately used a high dose of allopurinol to be sure that XO-
derived oxidative stress was completely abolished; previous
dose-response work in patients with heart failure suggests
that 600 mg per day is required to achieve this [8]. The
duration of therapy in our study was 20 weeks. It is possible
but unlikely that a longer duration of action is required
6
D
ow
nloaded from
 https://academ
ic.oup.com
/ageing/advance-article-abstract/doi/10.1093/ageing/afaa061/5823068 by guest on 07 M
ay 2020
Allopurinol in functional impairment
to demonstrate improvement in muscle efficiency if muscle
oxidative stress reduction by XO inhibition is themechanism
by which it occurs. The positive effect on urate levels and
improvement in 6-min walk distance argue in favour of this
duration being long enough to produce relevant biological
effects. Shorter durations of allopurinol therapy have shown
improvements in endothelial function in previous studies
[8,11], and as little as 1 week of allopurinol treatment
improved skeletal muscle and mitochondrial function in
preclinical models [6,30]. Muscle biopsies may have yielded
more information on muscle oxidative stress but this option
was declined by almost all patients and was therefore not
pursued. Data acquisition for MRS commenced immedi-
ately post-exercise, potentially missing the very start of the
recovery curve. Although we conducted the 6-min walk test
only once at baseline and once at follow-up, the parallel-
group design of our trial accounted for any learning effect,
and thus the improvement in the allopurinol arm cannot be
attributed to this.
In this present study, treatment allopurinol over 20 weeks
did not improve muscle energetics as measured by MR
spectroscopy. We observed a clinically relevant but modest
increase in the 6MWT. Future studies could prospectively
target those with sarcopenia, high urate and baseline muscle
oxidative stress. Such an approach would be most likely to
maximise the efficacy of allopurinol and would stand the best
chance of both confirming any effect on walk distance and
of elucidating the mechanism of any such effect.
Supplementary Data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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